RYR1 - Ryanodine Receptor 1

📖 Wiki Page

gene1422 wordssynced 2026-04-02

RYR1 — Ryanodine Receptor 1

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Ryanodine Receptor 1</th></tr>
<tr><td>Gene Symbol</td><td>RYR1</td></tr>
<tr><td>Full Name</td><td>Ryanodine Receptor 1</td></tr>
<tr><td>Chromosome</td><td>19q13.2</td></tr>
<tr><td>NCBI Gene ID</td><td>[6261](https://www.ncbi.nlm.nih.gov/gene/6261)</td></tr>
<tr><td>OMIM</td><td>180901</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000196218</td></tr>
<tr><td>UniProt ID</td><td>[P21810](https://www.uniprot.org/uniprot/P21810)</td></tr>
<tr><td>Protein Length</td><td>5,038 amino acids</td></tr>
<tr><td>Expression</td><td>Skeletal muscle, brain (neurons)</td></tr>
<tr><td>Associated Diseases</td><td>Central Core Disease, Malignant Hyperthermia, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Overview

...

RYR1 — Ryanodine Receptor 1

Overview

RYR1 (Ryanodine Receptor 1) encodes the skeletal muscle calcium release channel, a massive intracellular ion channel responsible for triggering muscle contraction through the release of calcium from the sarcoplasmic reticulum (SR)[@fill2002]. As the largest known ion channel complex, RYR1 forms a homotetramer of approximately 2.2 MDa, serving as the primary pathway for calcium-induced calcium release (CICR) in skeletal muscle cells. The discovery and cloning of RYR1 in the 1980s revolutionized our understanding of excitation-contraction (EC) coupling and continues to inform research into muscle physiology and disease[@zorzato1985][@maciel1989].

While RYR1 is predominantly expressed in skeletal muscle, significant expression also occurs in select neuronal populations within the central nervous system, particularly in the [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), and various cortical regions[@du2002]. Neuronal RYR1 plays crucial roles in regulating intracellular calcium dynamics, synaptic plasticity, and neuronal homeostasis. Dysregulation of neuronal RYR1 has been increasingly recognized as a contributing factor in the pathogenesis of neurodegenerative diseases, including [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and related disorders[@bermek2021].

Structure and Mechanism

Protein Architecture

RYR1 is an enormous protein comprising 5,038 amino acids that forms a homotetrameric channel complex[@beeck2008]. Each monomer contains:

N-terminal cytoplasmic domain (~2,500 residues): Forms a large cytoplasmic "foot" structure that spans the gap between the T-tubule and SR

Transmembrane region (~500 residues): Six transmembrane helices form the ion conduction pathway

C-terminal channel domain (~1,000 residues): Contains the Ca2+ binding sites and the conduction pathway

Calcium Release Mechanism

Mermaid diagram (expand to render)

Skeletal Muscle EC Coupling:

Voltage sensors in the T-tubule membrane (Cav1.1) detect depolarization
Direct mechanical coupling to RYR1 triggers channel opening
No calcium entry is required—purely mechanical signal transduction

Calcium-Induced Calcium Release (CICR):

RYR1 can be activated by elevated intracellular calcium
Creates positive feedback loop for calcium release
Important in cardiac muscle (via RYR2) and some neuronal contexts

Regulation

| Regulator | Effect | Mechanism |
|-----------|--------|-----------|
| Calcium | Activation | Direct binding to activation sites |
| Mg2+ | Inhibition | Competes with Ca2+ at activation sites |
| ATP | Activation | Stabilizes open state |
| Caffeine | Activation | Lowers activation threshold |
| Reactive oxygen species | Variable | Oxidative modifications |
| Calmodulin | Biphasic | Ca2+-dependent activation/inhibition |

Expression and Cellular Localization

Brain Expression

Within the nervous system, RYR1 exhibits a selective distribution[@du2002]:

| Brain Region | Expression Level | Cell Types |
|--------------|-----------------|------------|
| Hippocampus | Moderate-High | CA1-CA3 pyramidal neurons |
| Cerebellum | High | Purkinje cells |
| Cerebral Cortex | Moderate | Layer 5 pyramidal neurons |
| Basal Ganglia | Moderate | Striatal medium spiny neurons |
| Spinal Cord | High | Motor neurons |

Subcellular Distribution

In neurons, RYR1 localizes to:

Dendritic shafts: Distributed throughout dendritic arborization
Synaptic spines: Concentrated at postsynaptic sites
Somatic endoplasmic reticulum: Calcium release from internal stores
Axon terminals: Regulates neurotransmitter release
Mitochondrial proximity: Often near mitochondria for calcium crosstalk

Role in Neurodegenerative Diseases

Alzheimer's Disease

RYR1 dysfunction plays a significant role in AD pathogenesis through multiple mechanisms[@stutzmann2006][@mattson2008][@bermek2021]:

Calcium Dysregulation Hypothesis:
The calcium dysregulation hypothesis of AD posits that altered calcium signaling is a fundamental early event in disease pathogenesis. RYR1 contributes through:

Mermaid diagram (expand to render)

Enhanced channel activity: RYR1 channels in AD neurons show increased open probability

Oxidative modifications: ROS oxidize RYR1, altering gating properties

Fragmentation: Calpain-mediated cleavage produces hyperactive channel fragments

Upregulation: Increased RYR1 expression in AD brain

Consequences:

Mitochondrial dysfunction from excessive calcium uptake
Synaptic failure from impaired calcium handling
Tau pathology from calcium dysregulation
Abeta oligomers directly interact with RYR1

Parkinson's Disease

In Parkinson's disease, RYR1 contributes to dopaminergic neuron vulnerability[@chen2023]:

Mechanisms of Neurodegeneration:

Mitochondrial calcium overload: Excessive calcium uptake into mitochondria

Oxidative stress: Increased ROS production

Proteostasis disruption: Impaired autophagy and protein clearance

Synaptic dysfunction: Altered neurotransmitter release dynamics

Therapeutic Implications:

RYR1 antagonists protect dopaminergic neurons in models
RYR1 modulators reduce oxidative stress

Other Neurodegenerative Conditions

RYR1 dysfunction is implicated in:

Amyotrophic Lateral Sclerosis (ALS): Calcium dysregulation in motor neurons
Huntington's Disease: Altered RYR1 function in medium spiny neurons
Aging-related neurodegeneration: Progressive RYR1 dysfunction with age

Biological Functions

Excitation-Contraction Coupling

In skeletal muscle, RYR1 serves as the final effector of EC coupling:

Depolarization propagates along T-tubule

Cav1.1 detects depolarization

Direct mechanical coupling opens RYR1

Rapid Ca2+ releases from SR

Calcium binds troponin, enabling contraction

Synaptic Plasticity

Neuronal RYR1 plays essential roles in synaptic plasticity[@gomez2019]:

Long-Term Potentiation (LTP):

RYR1-mediated calcium release contributes to LTP induction
Calcium from RYR1 activates CaMKII

Long-Term Depression (LTD):

RYR1 contributes to LTD maintenance
RYR1-driven calcium influences AMPA receptor internalization

Calcium Homeostasis

ER calcium signaling
Calcium wave propagation
Store-operated calcium entry
Mitochondrial calcium regulation

Interaction Network

Protein Partners

| Partner | Interaction Type | Functional Effect |
|---------|-----------------|-------------------|
| Cav1.1 (skeletal) | Mechanical coupling | EC coupling trigger |
| Calmodulin | Calcium-dependent binding | Biphasic regulation |
| FKBP12 | Stabilizing binding | Enhanced channel function |
| Calsequestrin | Calcium storage | Calcium buffering |
| Junctophilin | Structural | T-SR anchoring |
| TRPC channels | Calcium influx | Store-operated entry |

Signaling Pathways

Calcineurin/NFAT pathway
CaMKII signaling
PKA signaling
MAPK pathway
Cell death pathways

Therapeutic Implications

Given the role of RYR1 dysregulation in neurodegeneration, therapeutic strategies include[@hernandez2021]:

RYR1 antagonists: Dantrolene (FDA-approved for malignant hyperthermia), novel selective antagonists

RYR1 stabilizers: FKBP12 binding enhancers, allosteric modulators

Gene therapy: Viral vectors, siRNA, CRISPR

Challenges:

Blood-brain barrier penetration
Selectivity (RYR1 vs RYR2/RYR3)
Therapeutic window

Animal Models

Knockout Models:

Constitutive Ryr1 knockout: embryonic lethal
Conditional neuronal knockout: viable with memory deficits

Transgenic Models:

Human RYR1 mutations: recapitulate disease phenotypes
Overexpression models: study gain-of-function

Genetic Considerations

Over 300 pathogenic RYR1 mutations cause:

Malignant hyperthermia
Central Core Disease
Neuromalignant syndrome
Arthrogryposis multiplex congenita

Some RYR1 variants may modify neurodegenerative disease risk.

Research Directions

Single-channel recordings for molecular understanding

Cryo-EM structures for high-resolution insights

Patient-derived neurons (iPSC models)

Optogenetic control for research

Clinical Trials

RYR1-Targeted Therapeutics

| Compound | Target | Phase | Status | Indication |
|----------|--------|-------|--------|------------|
| Dantrolene | RYR1 | II/III | Approved (MH) | Malignant Hyperthermia |
| Dexmedetomidine | RYR1 | II | Completed | Perioperative neuroprotection |
| S48168 | RYR1 | I | Completed | Heart failure |

RYR1 Modulators in Development

Clinical Development Status:

Dantrolene: FDA-approved for malignant hyperthermia, being repurposed for neurodegenerative diseases
Novel RYR1 antagonists: Several compounds in preclinical development for AD/PD
RYR1 stabilizers: FKBP12-binding compounds in early-stage trials

Challenges in RYR1-Targeted Therapy:

Blood-brain barrier penetration
Selectivity for neuronal RYR1 vs. muscle RYR1
Therapeutic window balancing efficacy and safety
RYR1 isoform-specific targeting (RYR1 vs. RYR2/RYR3)

Biomarker Development

RYR1 expression levels in CSF as disease progression markers
Calcium imaging biomarkers for RYR1 dysfunction
Genetic variants as risk stratification tools

Conclusion

RYR1 represents a critical nexus linking calcium signaling to both muscle function and neuronal health. Originally studied for its essential role in skeletal muscle contraction, RYR1 has emerged as an important player in neurodegenerative disease pathogenesis. The channel's dysfunction contributes to calcium dysregulation, mitochondrial failure, oxidative stress, and synaptic impairment—all hallmarks of AD, PD, and related disorders.

External Links

[NCBI Gene: RYR1](https://www.ncbi.nlm.nih.gov/gene/6261)
[UniProt: P21810](https://www.uniprot.org/uniprot/P21810)
[Ensembl: ENSG00000196218](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196218)
[GeneCards: RYR1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RYR1)
[OMIM: 180901](https://www.omim.org/entry/180901)

📖 View canonical wiki page →

RYR1 - Ryanodine Receptor 1

RYR1 — Ryanodine Receptor 1

Overview

RYR1 — Ryanodine Receptor 1

Overview

Structure and Mechanism

Protein Architecture

Calcium Release Mechanism

Regulation

Expression and Cellular Localization

Brain Expression

Subcellular Distribution

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Biological Functions

Excitation-Contraction Coupling

Synaptic Plasticity

Calcium Homeostasis

Interaction Network

Protein Partners

Signaling Pathways

Therapeutic Implications

Animal Models

Genetic Considerations

Research Directions

Clinical Trials

RYR1-Targeted Therapeutics

RYR1 Modulators in Development

Biomarker Development

Conclusion

See Also

External Links